Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Creo Medical Group's share price for the quarter that ended in Dec. 2025 was €0.106. Creo Medical Group's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 412.47 Mil. Therefore, Creo Medical Group's market cap for the quarter that ended in Dec. 2025 was €43.72 Mil.
Creo Medical Group's quarterly market cap
declined
from Dec. 2024 (€87.38 Mil) to Jun. 2025 (€59.40 Mil) and
declined
from Jun. 2025 (€59.40 Mil) to Dec. 2025 (€43.72 Mil).
Creo Medical Group's annual market cap
declined
from Dec. 2023 (€150.28 Mil) to Dec. 2024 (€87.38 Mil) and
declined
from Dec. 2024 (€87.38 Mil) to Dec. 2025 (€43.72 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Creo Medical Group's Enterprise Value for Today is €66.49 Mil.
Creo Medical Group (FRA:1RC) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Creo Medical Group Market Cap Related Terms
Creo Medical Group Market Cap Historical Data
* Premium members only.
The historical data trend for Creo Medical Group's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Creo Medical Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creo Medical Group Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's Market Cap distribution charts can be found below:
* The bar in red indicates where Creo Medical Group's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Creo Medical Group's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creo Medical Group (FRA:1RC) has a Market Cap of €76.12 Mil as of Jun. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Creo Medical Group and its competitors. According to the industry distribution chart, Creo Medical Group ranks #456 out of 867 companies in the Medical Devices & Instruments industry, placing it in the top 52.6%.
Is Creo Medical Group's Market Cap too high?
Creo Medical Group's current Market Cap is €76.12 Mil. Based on the distribution chart, Creo Medical Group ranks #456 out of 867 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Creo Medical Group has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Creo Medical Group ranks #456 out of 867 companies for Market Cap. This places Creo Medical Group in the lower half of its industry. The industry median Market Cap is 117.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 117.03, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Creo Medical Group and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 117.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creo Medical Group's current Market Cap is €76.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Creo Medical Group (FRA:1RC) has a current Market Cap of €76.12 Mil. The stock's GF Value™ is €0.18, compared to a current price of €0.15 — trading 19.4% below its estimated fair value. The current Market Cap is €76.12 Mil. Creo Medical Group's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Creo Medical Group (FRA:1RC), the current Market Cap is €76.12 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creo Medical Group (FRA:1RC) Overvalued in 2026?
Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued.
The current stock price of €0.15 is trading 19.4% below its estimated GF Value™ of €0.18.
Key valuation signals for FRA:1RC:
Market Cap: €76.12 Mil
GF Value™: €0.18 vs. price of €0.15 (19.4% below fair value)
No single metric tells the full story. See the FRA:1RC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
53GF Score
Get the complete analysis for FRA:1RC
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1RC has been successfully added to your 
